Innovation Pharmaceuticals Stock Performance
| IPIX Stock | USD 0.0003 0.0002 200.00% |
Innovation Pharmaceuticals holds a performance score of 19 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -2.11, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Innovation Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Innovation Pharmaceuticals is expected to outperform it. Use Innovation Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and price action indicator , to analyze future returns on Innovation Pharmaceuticals.
Risk-Adjusted Performance
19 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Innovation Pharmaceuticals are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Innovation Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.2 M | |
| Total Cashflows From Investing Activities | -4.1 M | |
| Free Cash Flow | -6.4 M |
Innovation |
Innovation Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.03 in Innovation Pharmaceuticals on September 4, 2024 and sell it today you would earn a total of 0.00 from holding Innovation Pharmaceuticals or generate 0.0% return on investment over 90 days. Innovation Pharmaceuticals is currently generating 13.8728% in daily expected returns and assumes 56.2426% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Innovation, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innovation Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innovation Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Innovation Pharmaceuticals, and traders can use it to determine the average amount a Innovation Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2467
| Best Portfolio | Best Equity | IPIX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 56.24 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.25 actual daily | 19 81% of assets perform better |
Based on monthly moving average Innovation Pharmaceuticals is performing at about 19% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innovation Pharmaceuticals by adding it to a well-diversified portfolio.
Innovation Pharmaceuticals Fundamentals Growth
Innovation Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Innovation Pharmaceuticals, and Innovation Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innovation Pink Sheet performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (339.83) % | |||
| Current Valuation | 7.56 M | |||
| Shares Outstanding | 488.32 M | |||
| Price To Earning | (7.57) X | |||
| Price To Book | 2.95 X | |||
| Price To Sales | 557.16 X | |||
| Revenue | 18 K | |||
| EBITDA | (6.54 M) | |||
| Cash And Equivalents | 2.97 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.24 M | |||
| Debt To Equity | 0.36 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (6.28 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 10.38 M | |||
| Retained Earnings | (87.38 M) | |||
| Current Asset | 529.15 K | |||
| Current Liabilities | 484.43 K | |||
About Innovation Pharmaceuticals Performance
Evaluating Innovation Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Innovation Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innovation Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Innovation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Innovation Pharmaceuticals performance evaluation
Checking the ongoing alerts about Innovation Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Innovation Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innovation Pharmaceuticals is way too risky over 90 days horizon | |
| Innovation Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K. | |
| Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Innovation Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innovation Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Innovation Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innovation Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innovation Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innovation Pharmaceuticals' pink sheet. These opinions can provide insight into Innovation Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.